Abstract
The epidermal growth factor receptor (EGFR) inhibitor erlotinib was found to significantly improve overall survival, time to progression, and cancer-related symptoms in locally advanced or metastatic non small cell lung carcinoma (NSCLC). Unfortunately, cutaneous side effects are not rare, the most common one being a follicular acneiform eruption. As it has been observed a positive correlation between rash severity and objective tumor response, it is critical for dermatologists early distinguish it from rashes carrying a different prognosis and needing a different management.
MeSH terms
-
Acneiform Eruptions / chemically induced*
-
Acneiform Eruptions / drug therapy
-
Administration, Cutaneous
-
Anti-Bacterial Agents / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Erlotinib Hydrochloride
-
Erythromycin / therapeutic use
-
Gels
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects*
-
Quinazolines / administration & dosage
-
Quinazolines / adverse effects*
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Gels
-
Protein Kinase Inhibitors
-
Quinazolines
-
Erythromycin
-
Erlotinib Hydrochloride